# TGTX catalysts: TG THERAPEUTICS, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/tgtx/catalysts

> TG THERAPEUTICS, INC. (TGTX) has 10 upcoming catalysts. The next is the BRIUMVI® (ublituximab) topline data readout, Jan to Apr 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, year only, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | TG THERAPEUTICS, INC. |
| Ticker | TGTX (Nasdaq) |
| SEC CIK | 1001316 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/tgtx |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 28, 2022 | [BRIUMVI® (ublituximab) FDA approval](https://sec-api.dev/pdufa/ublituximab) | TGTX |  | completed, approved | "On December 28, 2022, we announced the FDA approval of BRIUMVI for the treatment of RMS, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults, primarily based on results from the ULTIMATE I & II Phase 3 trials." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1001316/000143774925015804/tgtx20250331_10q.htm)) |
| December 28, 2022 | [Briumvi (ublituximab-xiiy) FDA approval](https://sec-api.dev/pdufa/ublituximab-xiiy) | TGTX | To treat relapsing forms of multiple sclerosis | completed, approved | "Briumvi \| ublituximab-xiiy \| 12/28/2022 \| To treat relapsing forms of multiple sclerosisDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022)) |
| 2025 | [BRIUMVI® (ublituximab) trial start](https://sec-api.dev/pdufa/ublituximab) | TGTX | RMS and in January 2025 | scheduled | "In August 2024, we announced the initiation of a Phase 1 clinical trial evaluating subcutaneous ublituximab in patients with RMS and in January 2025, at the Annual J.P. Morgan Healthcare Conference we announced our plans to commence a pivotal program in 2025 evaluating a subcutaneous ublituximab with an expected dosing frequency of at least every other month." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1001316/000143774925005908/tgtx20241231_10k.htm)) |
| March 3, 2025 | [TG THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/tgtx/catalysts) | TGTX |  | completed | "TG Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1001316/000143774925005802/ex_782107.htm)) |
| March 31, 2025 | [BRIUMVI® (ublituximab) FDA approval](https://sec-api.dev/pdufa/ublituximab) | TGTX |  | completed, approved | "At March 31, 2025, all our inventory was solely related to BRIUMVI, which was approved by the FDA on December 28, 2022, at which time we began to capitalize costs to manufacture BRIUMVI." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1001316/000143774925015804/tgtx20250331_10q.htm)) |
| May 5, 2025 | [BRIUMVI® (ublituximab) earnings report](https://sec-api.dev/pdufa/ublituximab) | TGTX |  | completed | "TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1001316/000143774925014402/ex_811168.htm)) |
| June 30, 2025 | [BRIUMVI® (ublituximab) FDA approval](https://sec-api.dev/pdufa/ublituximab) | TGTX |  | completed, approved | "At June 30, 2025, our inventory was solely related to BRIUMVI, which was approved by the FDA in December 2022, at which time we began to capitalize costs to manufacture BRIUMVI." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1001316/000143774925025745/tgtx20250630_10q.htm)) |
| August 4, 2025 | [BRIUMVI® (ublituximab) earnings report](https://sec-api.dev/pdufa/ublituximab) | TGTX |  | completed | "TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1001316/000143774925024480/ex_846995.htm)) |
| November 3, 2025 | [BRIUMVI® (ublituximab) earnings report](https://sec-api.dev/pdufa/ublituximab) | TGTX |  | completed | "TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1001316/000143774925032658/ex_860184.htm)) |
| February 26, 2026 | [BRIUMVI® (ublituximab) earnings report](https://sec-api.dev/pdufa/ublituximab) | TGTX |  | completed | "TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1001316/000143774926005733/ex_887198.htm)) |
| May 6, 2026 | [BRIUMVI® (ublituximab) earnings report](https://sec-api.dev/pdufa/ublituximab) | TGTX |  | completed | "TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1001316/000143774926015013/ex_926557.htm)) |
| May 27, 2026 | [BRIUMVI® (ublituximab) topline data readout](https://sec-api.dev/pdufa/ublituximab) | TGTX | relapsing forms of multiple sclerosis | completed, positive | "NEW YORK, May 27, 2026 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced positive topline results from the Phase 3 ENHANCE trial, a randomized, double-blind study evaluating a consolidated single infusion regimen for initiation of BRIUMVI® (ublituximab-xiiy) in adults with relapsing forms of multiple sclerosis (RMS)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1001316/000143774926018586/ex_968837.htm)) |
| Jun 2026 | [BRIUMVI® (ublituximab) topline data readout](https://sec-api.dev/pdufa/ublituximab) | TGTX | AChR-antibody-positive MG | completed, positive | "In June 2026, we announced positive topline data from an ongoing Phase 1 clinical trial evaluating subcutaneous BRIUMVI in patients with AChR-antibody-positive MG." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1001316/000143774926025955/tgtx20260630_10q.htm)) |
| Jun 2026 | [VYVGART (efgartigimod) topline data readout](https://sec-api.dev/pdufa/efgartigimod) | TGTX | myasthenia gravis | completed, positive | "•In June 2026, we announced positive topline data from an ongoing Phase 1 clinical trial evaluating subcutaneous BRIUMVI in patients with AChR-antibody-positive MG and the initiation of a Phase 2 clinical trial evaluating BRIUMVI as a maintenance therapy following induction with efgartigimod in adult patients with MG." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1001316/000162828026072257/tgtx-20260930.htm)) |
| August 3, 2026 | [BRIUMVI® (ublituximab) earnings report](https://sec-api.dev/pdufa/ublituximab) | TGTX |  | completed | "TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1001316/000143774926025304/ex_997107.htm)) |
| Oct 2026 to Jan 2027 | [BRIUMVI® (ublituximab) topline data readout](https://sec-api.dev/pdufa/ublituximab) | TGTX | Relapsing Multiple Sclerosis | scheduled | "NCT07211633 (A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-31 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07211633)) |
| October 2026 | [BRIUMVI® (ublituximab) primary completion](https://sec-api.dev/pdufa/ublituximab) | TGTX | Relapsing Multiple Sclerosis | delayed | "NCT07211633 (A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-31 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07211633)) |
| November 9, 2026 | [TG THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/tgtx/catalysts) | TGTX |  | completed | "TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1001316/000162828026071870/q3-26earningsprxexx991.htm)) |
| Jan to Apr 2027 | [BRIUMVI® (ublituximab) topline data readout](https://sec-api.dev/pdufa/ublituximab) | TGTX | Relapsing Multiple Sclerosis | scheduled | "NCT05877963 (Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-21 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05877963)) |
| January 2027 | [BRIUMVI® (ublituximab) primary completion](https://sec-api.dev/pdufa/ublituximab) | TGTX | Relapsing Multiple Sclerosis | scheduled | "NCT05877963 (Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-21 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05877963)) |
| Jul to Oct 2027 | [BRIUMVI® (ublituximab) topline data readout](https://sec-api.dev/pdufa/ublituximab) | TGTX | Multiple Sclerosis | scheduled | "NCT07503873 (A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-31 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07503873)) |
| July 2027 | [BRIUMVI® (ublituximab) primary completion](https://sec-api.dev/pdufa/ublituximab) | TGTX | Multiple Sclerosis | scheduled | "NCT07503873 (A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-31 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07503873)) |
| July 2028 | [BRIUMVI® (ublituximab) primary completion](https://sec-api.dev/pdufa/ublituximab) | TGTX | Myasthenia Gravis | scheduled | "NCT07673744 (A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-07-01 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07673744)) |
| Jul to Oct 2028 | [BRIUMVI® (ublituximab) topline data readout](https://sec-api.dev/pdufa/ublituximab) | TGTX | Myasthenia Gravis | scheduled | "NCT07673744 (A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-07-01 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07673744)) |
| Dec 2028 to Mar 2029 | [BRIUMVI® (ublituximab) topline data readout](https://sec-api.dev/pdufa/ublituximab) | TGTX | Schizophrenia | scheduled | "NCT07680946 (Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12-12 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07680946)) |
| December 2028 | [BRIUMVI® (ublituximab) primary completion](https://sec-api.dev/pdufa/ublituximab) | TGTX | Schizophrenia | scheduled | "NCT07680946 (Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12-12 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07680946)) |
| January 2030 | [BRIUMVI® (ublituximab) primary completion](https://sec-api.dev/pdufa/ublituximab) | TGTX | Relapsing Multiple Sclerosis | scheduled | "NCT07220252 (Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-01-01 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07220252)) |
| Jan to Apr 2030 | [BRIUMVI® (ublituximab) topline data readout](https://sec-api.dev/pdufa/ublituximab) | TGTX | Relapsing Multiple Sclerosis | scheduled | "NCT07220252 (Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-01-01 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07220252)) |

## Drugs

- [BRIUMVI® (ublituximab)](https://sec-api.dev/pdufa/ublituximab): relapsing forms of multiple sclerosis, achr-antibody-positive mg, rms and in january 2025, Relapsing Multiple Sclerosis, Schizophrenia, Multiple Sclerosis, Myasthenia Gravis
- [Briumvi (ublituximab-xiiy)](https://sec-api.dev/pdufa/ublituximab-xiiy): To treat relapsing forms of multiple sclerosis

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/tgtx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TGTX catalysts: TG THERAPEUTICS, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/tgtx/catalysts

```bibtex
@misc{secapidev_companies_tgtx_catalysts_20261116,
  title        = {TGTX catalysts: TG THERAPEUTICS, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/tgtx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_tgtx_catalysts_20261116","title":"TGTX catalysts: TG THERAPEUTICS, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/tgtx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
